Impact of Respiratory Syncytial Virus and Influenza Virus Infection in the Adult Population in Spain between 2012 and 2020
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Data Sources
2.2. Data Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Mizgerd, J.P. Lung infection—A public health priority. PLoS Med. 2006, 3, e76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greene, G.; Hood, K.; Little, P.; Verheij, T.; Goossens, H.; Coenen, S.; Butler, C.C. Towards clinical definitions of lower respiratory tract infection (LRTI) for research and primary care practice in Europe: An international consensus study. Prim. Care Respir. J. 2011, 20, 299–306. [Google Scholar] [CrossRef] [PubMed]
- Madhi, S.A.; Klugman, K.P. The Vaccine Trialist Group A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 2004, 10, 811–813. [Google Scholar] [CrossRef] [PubMed]
- Voiriot, G.; Visseaux, B.; Cohen, J.; Nguyen, L.B.; Neuville, M.; Morbieu, C.; Burdet, C.; Radjou, A.; Lescure, F.X.; Smonig, R.; et al. Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia. Crit. Care 2016, 20, 375. [Google Scholar] [CrossRef] [Green Version]
- Malosh, R.E.; Martin, E.T.; Ortiz, J.R.; Monto, A.S. The risk of lower respiratory tract infection following influenza virus infection: A systematic and narrative review. Vaccine 2018, 36, 141–147. [Google Scholar] [CrossRef]
- Ruuskanen, O.; Lahti, E.; Jennings, L.C.; Murdoch, D.R. Viral pneumonia. Lancet 2011, 377, 1264–1275. [Google Scholar] [CrossRef]
- Shi, T.; McLean, K.; Campbell, H.; Nair, H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: A systematic review and meta-analysis. J. Glob. Health 2015, 5, 010408. [Google Scholar] [CrossRef]
- Vos, L.M.; Bruyndonckx, R.; Zuithoff, N.P.A.; Little, P.; Oosterheert, J.J.; Broekhuizen, B.D.L.; Lammens, C.; Loens, K.; Viveen, M.; Butler, C.C.; et al. Lower respiratory tract infection in the community: Associations between viral aetiology and illness course. Clin. Microbiol. Infect. 2021, 27, 96–104. [Google Scholar] [CrossRef]
- Pattemore, P.K.; Jennings, L.C. Chapter 31—Epidemiology of Respiratory Infections. In Pediatric Respiratory Medicine, 2nd ed.; Taussig, L.M., Landau, L.I., Eds.; Mosby: Philadelphia, PA, USA, 2008; pp. 435–452. [Google Scholar]
- Li, Y.; Wang, X.; Blau, D.M.; Caballero, M.T.; Feikin, D.R.; Gill, C.J.; Madhi, S.; Omer, S.B.; Simões, E.A.F.; Campbell, H.; et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet 2022, 399, 2047–2064. [Google Scholar] [CrossRef]
- Falsey, A.R.; Walsh, E.E. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 2000, 13, 371–384. [Google Scholar] [CrossRef]
- Walsh, E.E. Respiratory syncytial virus infection in adults. Semin. Respir. Crit. Care Med. 2011, 32, 423–432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sundaram, M.E.; Meece, J.K.; Sifakis, F.; Gasser, R.A., Jr.; Belongia, E.A. Medically attended respiratory syncytial virus infections in adults aged ≥ 50 years: Clinical characteristics and outcomes. Clin. Infect. Dis. 2014, 58, 342–349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ison, M.G.; Hirsch, H.H. Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs. Clin. Microbiol. Rev. 2019, 32, e00042-19. [Google Scholar] [CrossRef] [Green Version]
- Falsey, A.R.; Hennessey, P.A.; Formica, M.A.; Cox, C.; Walsh, E.E. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults. N. Engl. J. Med. 2005, 352, 1749–1759. [Google Scholar] [CrossRef] [PubMed]
- Hansen, C.L.; Chaves, S.S.; Demont, C.; Viboud, C. Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999–2018. JAMA Netw. Open 2022, 5, e220527. [Google Scholar] [CrossRef]
- Branche, A.R.; Falsey, A.R. Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem. Drugs Aging 2015, 32, 261–269. [Google Scholar] [CrossRef]
- Binder, W.; Thorsen, J.; Borczuk, P. RSV in adult ED patients: Do emergency providers consider RSV as an admission diagnosis? Am. J. Emerg. Med. 2017, 35, 1162–1165. [Google Scholar] [CrossRef]
- van Summeren, J.; Meijer, A.; Aspelund, G.; Casalegno, J.S.; Erna, G.; Hoang, U.; Lina, B.; de Lusignan, S.; Teirlinck, A.C.; Thors, V.; et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: What can we expect in the coming summer and autumn/winter? Eurosurveillance 2021, 26, 2100639. [Google Scholar] [CrossRef]
- Ackerson, B.; Tseng, H.F.; Sy, L.S.; Solano, Z.; Slezak, J.; Luo, Y.; Fischetti, C.; Shinde, V. Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. Clin. Infect. Dis. 2019, 69, 197–203. [Google Scholar] [CrossRef] [Green Version]
- Young, M.; Smitherman, L. Socioeconomic Impact of RSV Hospitalization. Infect. Dis. Ther. 2021, 10, 35–45. [Google Scholar] [CrossRef]
- Domachowske, J.B.; Anderson, E.J.; Goldstein, M. The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infect. Dis. Ther. 2021, 10, 47–60. [Google Scholar] [CrossRef] [PubMed]
- Thornhill, E.M.; Salpor, J.; Verhoeven, D. Respiratory syntycial virus: Current treatment strategies and vaccine approaches. Antivir. Chem. Chemother. 2020, 28, 2040206620947303. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez del Águila, M.; Perea-Milla, E.; Librero, J.; BuzónBarrera, M.; Rivas Ruiz, F. Atlas VPM Nº 4. Análisis del Control de Calidad del Conjunto Mínimo de Datos Básicos de Andalucía en los años 2000 a 2003. Sevilla. Available online: https://cienciadedatosysalud.org/wp-content/uploads/2019/06/An%C3%A1lisis-del-control-de-calidad-del-Conjunto-M%C3%ADnimo-de-Datos-B%C3%A1sicos-de-Andaluc%C3%ADa-de-los-a%C3%B1os-2000-a-2003.pdf (accessed on 5 August 2022).
- Ministerio de Sanidad y Consumo; Agencia de Calidad del Sistema Nacional de Salud; Instituto de Información Sanitaria. Metodología de Análisis de la Hospitalización en el Sistema Nacional de Salud. Modelo de Indicadores Basado en el Registro de Altas (CMBD). Available online: https://www.mscbs.gob.es/estadEstudios/estadisticas/docs/metod_modelo_cmbd_pub.pdf (accessed on 5 August 2022).
- Instituto Nacional de Estadística (INE). Demography and Population. Available online: https://ine.es/dyngs/INEbase/en/categoria.htm?c=Estadistica_P&cid=1254734710984 (accessed on 3 August 2022).
- Lee, N.; Lui, C.Y.G.; Wong, K.T.; Li, T.C.M.; Tse, E.C.M.; Chan, J.Y.C.; Yu, J.; Wong, S.S.M.; Choi, K.W.; Wong, R.Y.K.; et al. High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clin. Infect. Dis. 2013, 57, 1069–1077. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Volling, C.; Hassan, K.; Mazzulli, T.; Green, K.; Al-Den, A.; Hunter, P.; Mangat, R.; Ng, J.; McGeer, A. Respiratory syncytial virus infection-associated hospitalization in adults: A retrospective cohort study. BMC Infect. Dis. 2014, 14, 665. [Google Scholar] [CrossRef] [Green Version]
- Atamna, A.; Babich, T.; Froimovici, D.; Yahav, D.; Sorek, N.; Ben-Zvi, H.; Leibovici, L.; Bishara, J.; Avni, T. Morbidity and mortality of respiratory syncytial virus infection in hospitalized adults: Comparison with seasonal influenza. Int. J. Infect. Dis. 2021, 103, 489–493. [Google Scholar] [CrossRef]
- Pastula, S.T.; Hackett, J.; Coalson, J.; Jiang, X.; Villafana, T.; Ambrose, C.; Fryzek, J. Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infect. Dis. 2017, 4, ofw270. [Google Scholar] [CrossRef] [Green Version]
- Kwon, Y.S.; Park, S.H.; Kim, M.A.; Kim, H.J.; Park, J.S.; Lee, M.Y.; Lee, C.W.; Dauti, S.; Choi, W.I. Risk of mortality associated with respiratory syncytial virus and influenza infection in adults. BMC Infect. Dis. 2017, 17, 785. [Google Scholar] [CrossRef] [Green Version]
- Ivey, K.S.; Edwards, K.M.; Talbot, H.K. Respiratory Syncytial Virus and Associations with Cardiovascular Disease in Adults. J. Am. Coll. Cardiol. 2018, 71, 1574–1583. [Google Scholar] [CrossRef]
- Cohen, R.; Babushkin, F.; Geller, K.; Finn, T. Characteristics of hospitalized adult patients with laboratory documented Influenza A, B and Respiratory Syncytial Virus—A single center retrospective observational study. PLoS ONE 2019, 14, e0214517. [Google Scholar] [CrossRef]
- Chatterjee, A.; Mavunda, K.; Krilov, L.R. Current State of Respiratory Syncytial Virus Disease and Management. Infect. Dis. Ther. 2021, 10, 5–16. [Google Scholar] [CrossRef]
- de Miguel Díez, J.; López de Andrés, A.; Jiménez García, R. The Minimum Basic Data Set (MBDS), Our Big Data for the Epidemiological Investigation of Respiratory Diseases. Arch. Bronconeumol. 2020, 56, 267–268. [Google Scholar] [CrossRef] [PubMed]
- Peiró, S.; Librero, J. The quality assessment from the minimum basic hospital discharge data set. Rev. Neurol. 1999, 29, 651–661. [Google Scholar] [PubMed]
- Cai, W.; Tolksdorf, K.; Hirve, S.; Schuler, E.; Zhang, W.; Haas, W.; Buda, S. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir. Viruses 2020, 14, 630–637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamin, D.; Jones, F.K.; DeVincenzo, J.P.; Gertler, S.; Kobiler, O.; Townsend, J.P.; Galvani, A.P. Vaccination strategies against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 2016, 113, 13239–13244. [Google Scholar] [CrossRef] [PubMed]
ICD-9-CM Codes (Cases Collected from 2012 to 2015) | |
---|---|
079.6 | Respiratory syncytial virus infection |
466.0 | Acute bronchitis |
466.1 | Acute bronchiolitis |
466.11 | Acute bronchiolitis due to respiratory syncytial virus |
480.1 | Pneumonia due to respiratory syncytial virus |
487.0 | Influenza with pneumonia |
487.1 | Influenza with other respiratory manifestations |
490 | Bronchitis, not specified as acute or chronic |
493.9 | Asthma unspecified |
ICD-10-CM Codes (Cases Collected from 2016 to 2020) | |
B97.4 | Respiratory syncytial virus as the cause of diseases classified elsewhere |
J12.1 | Respiratory syncytial virus pneumonia |
J20.5 | Acute bronchitis due to respiratory syncytial virus |
J20.9 | Acute bronchitis, unspecified |
J21.0 | Acute bronchiolitis due to respiratory syncytial virus |
J21.9 | Acute bronchiolitis, unspecified |
J11.0 | Influenza due to unidentified influenza virus with pneumonia |
J11.1 | Influenza due to unidentified influenza virus with other respiratory manifestations |
J40 | Bronchitis, not specified as acute or chronic |
J45.9 | Other and unspecified asthma |
Nonspecified Infection | RSV-Related Infection | Influenza-Related Infection | ||||
---|---|---|---|---|---|---|
Year | N | Annual Rate a | N | Annual Rate | N | Annual Rate |
2012 | 129,628 | 28.89 | 13,647 | 2.22 | 2527 | 0.54 |
2013 | 133,969 | 29.66 | 11,262 | 1.94 | 3146 | 0.66 |
2014 | 140,318 | 30.93 | 13,018 | 2.33 | 4739 | 1.03 |
2015 | 149,398 | 32.86 | 14,659 | 2.65 | 9045 | 2.00 |
2016 | 143,298 | 31.38 | 15,089 | 2.80 | 7207 | 1.56 |
2017 | 159,644 | 34.74 | 16,973 | 3.29 | 7064 | 1.55 |
2018 | 172,387 | 37.22 | 18,726 | 3.76 | 8697 | 1.89 |
2019 | 168,735 | 35.98 | 22,180 | 4.59 | 2369 | 0.50 |
2020 | 136,785 | 28.88 | 12,240 | 2.58 | 1494 | 0.32 |
Total | 1,334,162 | 31.74 | 137,794 | 3.28 | 46,288 | 1.10 |
p-value | <0.001 | <0.001 | <0.001 |
Nonspecified Infection | RSV-Related Infection | Influenza-Related Infection | ||||
---|---|---|---|---|---|---|
Age Group | N (%) | Annual Rate a | N (%) | Annual Rate a | N (%) | Annual Rate a |
<1 yr | 61,053 (4.6) | 168.15 | 95,647 (69.4) | 263.42 | 2593 (5.6) | 7.14 |
(167.77–168.53) | (262.97–263.87) | (7.05–7.23) | ||||
1 yr | 23,334 (1.7) | 61.06 | 12,744 (9.2) | 33.35 | 1253 (2.7) | 3.28 |
(60.06–61.3) | (33.17–33.53) | (3.22–3.34) | ||||
2–4 yr | 36,447 (2.7) | 29.76 | 7337 (5.3) | 5.99 | 2047 (4.4) | 1.67 |
(29.66–29.86) | (5.95–6.03) | (1.65–1.69) | ||||
5–14 yr | 40,500 (3.0) | 9.38 | 1348 (1.0) | 0.31 | 1851 (4.0) | 0.43 |
(9.35–9.41) | (0.30–0.32) | (0.42–0.44) | ||||
15–19 yr | 18,509 (1.4) | 9.18 | 133 (0.1) | 0.07 | 348 (0.8) | 0.17 |
(9.14–9.22) | (0.07–0.07) | (0.16–0.18) | ||||
20–29 yr | 57,204 (4.3) | 12.79 | 244 (0.2) | 0.05 | 1034 (2.2) | 0.23 |
(12.76–12.82) | (0.05–0.05) | (0.23–0.23) | ||||
30–39 yr | 94,060 (7.1) | 15.22 | 433 (0.3) | 0.07 | 2016 (4.4) | 0.30 |
(15.19–15.25) | (0.07–0.07) | (0.33–0.33) | ||||
40–49 yr | 96,217 (7.2) | 13.95 | 857 (0.6) | 0.12 | 2892 (6.2) | 0.42 |
(13.92–13.98) | (0.12–0.12) | (0.42–0.42) | ||||
50–59 yr | 115,098 (8.6) | 19.45 | 1739 (1.3) | 0.29 | 4337 (9.4) | 0.73 |
(19.41–19.49) | (0.29–0.29) | (0.72–0.74) | ||||
60–69 yr b | 155,522 (11.7) | 34.46 | 3023 (2.2) | 0.67 | 6318 (13.6) | 1.40 |
(34.41–34.51) | (0.66–0.68) | (1.39–1.41) | ||||
70–79 yr | 241,101 (18.1) | 73.67 | 4830 (3.5) | 1.48 | 8535 (18.4) | 2.61 |
(73.58–73.76) | (1.47–1.49) | (2.59–2.63) | ||||
80–89 yr | 307,287 (23.0) | 149.82 | 7065 (5.1) | 3.44 | 10,180 (22.0) | 4.96 |
(149.67–149.97) | (3.41–3.47) | (4.93–4.99) | ||||
≥90 yr | 87,830 (6.6) | 204.03 | 2394 (1.7) | 5.56 | 2884 (6.2) | 6.70 |
(203.65–204.41) | (5.49–5.63) | (6.62–6.78) | ||||
Total | 1,334,162 (100.0) | 31.74 | 137,794 (100.0) | 3.28 | 46,288 (100.0) | 1.10 |
(31.72–31.76) | (3.27–3.29) | (1.1–1.1) | ||||
p-value | <0.001 | <0.001 | <0.001 |
Nonspecified Infection | RSV-Related Infection | Influenza-Related Infection | ||||
---|---|---|---|---|---|---|
Year | N | CFR a | N | CFR | N | CFR |
2012 | 4604 | 3.55 | 34 | 0.25 | 93 | 3.68 |
2013 | 4599 | 3.43 | 33 | 0.29 | 102 | 3.24 |
2014 | 4904 | 3.49 | 57 | 0.44 | 222 | 4.68 |
2015 | 5723 | 3.83 | 69 | 0.47 | 472 | 5.22 |
2016 | 5383 | 3.76 | 105 | 0.70 | 249 | 3.45 |
2017 | 6257 | 3.92 | 201 | 1.18 | 429 | 6.07 |
2018 | 6682 | 3.88 | 299 | 1.60 | 463 | 5.32 |
2019 | 6397 | 3.79 | 452 | 2.04 | 144 | 6.08 |
2020 | 6759 | 4.94 | 401 | 3.28 | 80 | 5.35 |
Total | 51,308 | 3.85 | 1651 | 1.20 | 2254 | 4.87 |
p-value | <0.001 | <0.001 | <0.001 |
Nonspecified Infection | RSV-Related Infection | Influenza-Related Infection | ||||
---|---|---|---|---|---|---|
Age Group | N (%) | Annual Rate a | N (%) | Annual Rate a | N (%) | Annual Rate a |
<1 yr | 53 (0.1) | 0.09 | 84 (5.1) | 0.09 | 4 (0.2) | 0.15 |
(0.07–0.11) | (0.07–0.11) | (0–0.3) | ||||
1 yr | 17 (0.0) | 0.07 | 19 (1.2) | 0.15 | 3 (0.1) | 0.24 |
(0.04–0.1) | (0.08–0.22) | (0.03–0.51) | ||||
2–4 yr | 15 (0.0) | 0.04 | 17 (1.0) | 0.23 | 2 (0.1) | 0.10 |
(0.02–0.06) | (0.12–0.34) | (0.04–0.24) | ||||
5–14 yr | 49 (0.1) | 0.12 | 25 (1.5) | 1.85 | 21 (0.9) | 1.13 |
(0.09–0.15) | (1.13–2.57) | (0.65–1.61) | ||||
15–19 yr | 43 (0.1) | 0.23 | 3 (0.2) | 2.26 | 4 (0.2) | 1.15 |
(0.16–0.3) | (0.27–4.79) | (0.03–2.27) | ||||
20–29 yr | 157 (0.3) | 0.27 | 9 (0.5) | 3.69 | 18 (0.8) | 1.74 |
(0.23–0.31) | (1.32–6.06) | (0.94–2.54) | ||||
30–39 yr | 374 (0.7) | 0.40 | 12 (0.7) | 2.77 | 23 (1.0) | 1.14 |
(0.36–0.44) | (1.22–4.32) | (0.68–1.6) | ||||
40–49 yr | 1054 (2.1) | 1.10 | 36 (2.2) | 4.20 | 71 (3.1) | 2.46 |
(1.03–1.17) | (2.86–5.54) | (1.9–3.02) | ||||
50–59 yr | 2424 (4.7) | 2.11 | 76 (4.6) | 4.37 | 178 (7.9) | 4.10 |
(2.03–2.19) | (3.41–5.33) | (3.51–4.69) | ||||
60–69 yr b | 4701 (9.2) | 3.02 | 179 (10.8) | 5.92 | 284 (12.6) | 4.50 |
(2.93–3.11) | (5.08–6.76) | (3.99–5.01) | ||||
70–79 yr | 9988 (19.5) | 4.14 | 305 (18.5) | 6.31 | 451 (20.0) | 5.28 |
(4.06–4.22) | (5.62–7) | (4.81–5.75) | ||||
80–89 yr | 21,994 (42.9) | 7.16 | 600 (36.3) | 8.49 | 791 (35.1) | 7.77 |
(7.07–7.25) | (7.84–9.14) | (7.25–8.29) | ||||
≥90 yr | 10,439 (20.3) | 11.89 | 286 (17.3) | 11.95 | 404 (17.9) | 14.01 |
(11.68–12.1) | (10.65–13.25) | (12.74–15.28) | ||||
Total | 51,308 (100.0) | 3.85 | 1651 (100.0) | 1.20 | 2254 (100.0) | 4.87 |
(3.82–3.88) | (1.14–1.26) | (4.67–5.07) | ||||
p-value | <0.001 | <0.001 | <0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Heppe-Montero, M.; Gil-Prieto, R.; del Diego Salas, J.; Hernández-Barrera, V.; Gil-de-Miguel, Á. Impact of Respiratory Syncytial Virus and Influenza Virus Infection in the Adult Population in Spain between 2012 and 2020. Int. J. Environ. Res. Public Health 2022, 19, 14680. https://doi.org/10.3390/ijerph192214680
Heppe-Montero M, Gil-Prieto R, del Diego Salas J, Hernández-Barrera V, Gil-de-Miguel Á. Impact of Respiratory Syncytial Virus and Influenza Virus Infection in the Adult Population in Spain between 2012 and 2020. International Journal of Environmental Research and Public Health. 2022; 19(22):14680. https://doi.org/10.3390/ijerph192214680
Chicago/Turabian StyleHeppe-Montero, Marco, Ruth Gil-Prieto, Jorge del Diego Salas, Valentín Hernández-Barrera, and Ángel Gil-de-Miguel. 2022. "Impact of Respiratory Syncytial Virus and Influenza Virus Infection in the Adult Population in Spain between 2012 and 2020" International Journal of Environmental Research and Public Health 19, no. 22: 14680. https://doi.org/10.3390/ijerph192214680